Goldman Sachs Group, Inc. (The) reaffirmed their neutral rating on shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research note published on Friday. Goldman Sachs Group, Inc. (The) currently has a $124.00 price target on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the company. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the company a buy rating in a research note on Thursday, June 8th. Zacks Investment Research upgraded GW Pharmaceuticals PLC from a hold rating to a buy rating and set a $119.00 price target for the company in a research note on Monday, July 17th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the company a buy rating in a research note on Tuesday, August 8th. BidaskClub upgraded GW Pharmaceuticals PLC from a sell rating to a hold rating in a research note on Wednesday, June 21st. Finally, ValuEngine upgraded GW Pharmaceuticals PLC from a sell rating to a hold rating in a research note on Wednesday, June 21st. One analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has an average rating of Buy and an average target price of $143.05.
GW Pharmaceuticals PLC (GWPH) traded down 4.01% during midday trading on Friday, reaching $109.95. The company had a trading volume of 317,903 shares. The firm has a 50-day moving average of $106.16 and a 200 day moving average of $108.22. GW Pharmaceuticals PLC has a 1-year low of $92.65 and a 1-year high of $136.95. The company’s market capitalization is $2.78 billion.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The business had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $2.10 million. During the same quarter last year, the business posted ($0.05) earnings per share. On average, equities research analysts forecast that GW Pharmaceuticals PLC will post ($5.94) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “GW Pharmaceuticals PLC’s (GWPH) Neutral Rating Reaffirmed at Goldman Sachs Group, Inc. (The)” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/10/07/gw-pharmaceuticals-plcs-gwph-neutral-rating-reaffirmed-at-goldman-sachs-group-inc-the.html.
Several large investors have recently made changes to their positions in GWPH. Janus Henderson Group PLC purchased a new position in shares of GW Pharmaceuticals PLC in the second quarter worth about $70,128,000. Redmile Group LLC raised its stake in shares of GW Pharmaceuticals PLC by 33.8% in the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock worth $44,605,000 after purchasing an additional 112,392 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of GW Pharmaceuticals PLC in the first quarter worth about $10,909,000. Nomura Holdings Inc. purchased a new position in shares of GW Pharmaceuticals PLC in the first quarter worth about $9,389,000. Finally, Employees Retirement System of Texas purchased a new position in shares of GW Pharmaceuticals PLC in the second quarter worth about $5,313,000. Hedge funds and other institutional investors own 75.06% of the company’s stock.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.